Cellular junction dynamics and Alzheimer's disease: a comprehensive review

Neurodegenerative disorders like Alzheimer's disease (AD) involve complex interactions between cellular structures and brain homeostasis. Established knowledge shows that AD is marked by neuronal damage and cognitive decline. However, the specific role of cellular junctions in AD progression remains unclear. Prior research has shown that the blood-brain barrier (BBB) is vital for maintaining brain stability. That uncertainty drove the need to examine how BBB integrity and junctional proteins contribute to AD pathology. No prior work had resolved the exact mechanisms linking junctional dysfunction and AD advancement. This gap motivated a comprehensive review of BBB and junctional components in AD. The hippocampus, a region heavily affected in AD, is a focal point for these studies. Understanding how junctional proteins like claudins and connexins are altered in AD could provide new insights into disease mechanisms.

This review aims to clarify how cellular junctions and the BBB contribute to Alzheimer's disease progression. The specific problem is the lack of detailed understanding about how junctional proteins influence AD pathology. The motivation stems from the need to identify molecular mechanisms that could lead to new therapeutic strategies. The study focuses on the BBB and its junctional components, such as tight junctions and adherence junctions. It also examines how these structures interact with AD-related processes in the hippocampus. The goal is to synthesize current evidence on junctional dysfunctions and their role in AD. By analyzing existing literature, the authors seek to highlight key findings about BBB permeability and junctional alterations. This work may help guide future research into BBB-targeted interventions for AD.

The authors conducted a comprehensive review of existing literature on BBB and cellular junctions in AD. They analyzed studies focusing on junctional proteins like claudins, occludin, and connexins. The review approach included examining how these proteins are altered in AD pathology. The authors also evaluated the role of adherence junctions involving VE-cadherin and Nectins. They synthesized findings from multiple studies to identify common patterns of junctional dysfunction. The review included a focus on the hippocampus as a key region affected in AD. The authors compared data from different studies to assess the consistency of junctional changes in AD. This approach allowed them to propose potential mechanisms linking junctional alterations to AD progression.

The strongest finding is the association between junctional protein alterations and AD progression. Studies show that claudins and occludin are significantly reduced in AD patients. Tight junction disruption leads to increased BBB permeability, which is linked to cognitive decline. Gap junctions formed by connexins also show abnormal expression in AD-affected regions. Adherence junctions involving VE-cadherin are compromised, contributing to BBB instability. These changes are most pronounced in the hippocampus, a region critical for memory. The review found consistent evidence that junctional dysfunction correlates with AD severity. These findings suggest that junctional integrity is a key factor in maintaining BBB function and neuronal health.

The authors propose that junctional dysfunction is closely linked to AD progression. Synthesis of the literature suggests that BBB permeability is a significant contributor to AD pathology. The review highlights the importance of tight junction proteins like claudins and occludin in maintaining BBB integrity. Adherence junctions involving VE-cadherin also play a crucial role in BBB stability. The findings suggest that junctional alterations in the hippocampus are a key factor in AD advancement. The authors emphasize the need to further investigate how these junctional changes affect neuronal signaling. This work may guide future research into therapeutic strategies targeting junctional proteins. The review provides a foundation for understanding how BBB and junctional dysfunctions contribute to AD.